founded in 1994, shanghai fosun pharmaceutical (group) co., ltd. ("fosun pharma"; stock code: 600196. sh, 02196. hk) is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in china. fosun pharma directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. as a shareholder of sinopharm co., ltd., fosun pharma expands its areas in the pharmaceutical distribution and retail business.
fosun pharma is patient-centered and clinical needs-oriented. the company enriches its innovative product pipeline through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and in-depth incubation. fosun pharma has formed technological platforms for innovative small molecule drugs, antibody drugs, and cell therapy with a focus on key disease areas including oncology and immunomodulation, metabolism and digestive system, and central nervous system. fosun pharma also vigorously explores cutting-edge technologies, such as rna, gene therapy, adc and protac, to enhance its innovation capabilities.
guided by the 4in strategy (innovation, internationalization, intelligentization, and integration), fosun pharma will uphold the development model of “innovation transformation, integrated operation, and steady growth", with the mission of creating shareholder values through strengthening its independent r&d and external cooperation and enriching its product pipelines, as well as promoting the global networks and enhancing operational efficiency. fosun pharma will actively promote the digital and physical business layout in the pharmaceutical and healthcare industry and is committed to becoming a first-class enterprise in the global medical and health market.
- 39,005 million
- fy2021 revenue
- 3,277 million
- fy 2021 net profit attributable to shareholders of the listed company after the one-off gain
- 4,975 million
- fy 2021 r&d expenditure
- global employees
- five-star (excellence)
- 2021 corporate social responsibility report rating
- msci esg rating
unit: rmb million